dl-Tetrandrine
dl-Tetrandrine is an orally active and brain-penetrant calcium channel blocker that inhibits voltage-dependent calcium channels. dl-Tetrandrine selectively blocks Ca2+ influx with an IC50 value of approximately 1-10 μM. dl-Tetrandrine exerts anti-inflammatory, immunosuppressive, and anti-arrhythmic activities by inhibiting intracellular calcium overload, and can reverse multidrug resistance in tumor cells. dl-Tetrandrine is promising for research of autoimmune diseases (such as rheumatoid arthritis), cardiovascular diseases, and tumor drug resistance reversal.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 23495-89-8
- Formule: C38H42N2O6
- Masse moléculaire:622.75
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A673 | GI50 |
4 μM
Compound: 16
|
Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| CCRF-CEM | IC50 |
15.8 μM
Compound: 1
|
Antiproliferative activity against vincristine-resistant human CEM cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-blue cell viability assay
Antiproliferative activity against vincristine-resistant human CEM cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-blue cell viability assay
|
[PMID: 32942071] |
| ECa-109 cell line | IC50 |
29.37 nM
Compound: TET
|
Reversal of VCR -resistance in human Eca-109 cells assessed as vincristine IC50 by measuring cell viability incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
Reversal of VCR -resistance in human Eca-109 cells assessed as vincristine IC50 by measuring cell viability incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
|
[PMID: 36892076] |
| ECa-109 cell line | IC50 |
29.4 nM
Compound: TET
|
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
|
[PMID: 36892076] |
| HCC1806 | GI50 |
5.1 μM
Compound: 16
|
Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| HCC1937 | GI50 |
4.2 μM
Compound: 16
|
Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| HCC70 | GI50 |
3.4 μM
Compound: 16
|
Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| HEK-293T | CC50 |
>1 μM
Compound: 1; tet
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability by CellTiter-Glo assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability by CellTiter-Glo assay
|
[PMID: 37043739] |
| HEL | IC50 |
16.78 μM
Compound: Tetrandrine
|
Cytotoxicity against human HEL cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HEL cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| HEL | IC50 |
19.74 μM
Compound: Tetrandrine
|
Cytotoxicity against human HEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| HEL | IC50 |
7.45 μM
Compound: Tet
|
Antiproliferative activity against HEL cells after 48 hrs by MTT assay
Antiproliferative activity against HEL cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| HeLa | IC50 |
2.16 μM
Compound: Tetrandrine
|
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
|
[PMID: 29624387] |
| HepG2 | IC50 |
6.82 μM
Compound: Tetrandrine
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28057423] |
| K562 | IC50 |
11.76 μM
Compound: Tet
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| K562 | IC50 |
13.81 μM
Compound: Tetrandrine
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| K562 | IC50 |
6.43 μM
Compound: Tetrandrine
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| KB | ED50 |
5800 nM
Compound: 16
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 9917283] |
| KB-V1 | ED50 |
3.7 μg/mL
Compound: 1
|
Cytotoxicity against human multidrug-resistant KBV1 cells
Cytotoxicity against human multidrug-resistant KBV1 cells
|
[PMID: 8450318] |
| L02 | IC50 |
44.25 μM
Compound: Tet
|
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| MCF7 | IC50 |
19.58 μM
Compound: Tetrandrine
|
Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| MCF7 | IC50 |
8.62 μM
Compound: Tetrandrine
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 28057423] |
| MDA-MB-231 | GI50 |
5 μM
Compound: 16
|
Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| MDA-MB-231 | IC50 |
18.45 μM
Compound: Tetrandrine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| MDA-MB-231 | IC50 |
21.97 μM
Compound: Tetrandrine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| MDA-MB-231 | IC50 |
8.94 μM
Compound: Tet
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| MDA-MB-453 | GI50 |
3.3 μM
Compound: 16
|
Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| P388 | ED50 |
0.4 μg/mL
Compound: 1
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 8450318] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
10 nM
Compound: Fanchinin
|
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
|
[PMID: 15743190] |
| PC-3 | IC50 |
5.86 μM
Compound: Tet
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| PC-3 | IC50 |
7.87 μM
Compound: Tetrandrine
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| PLC-PRF-5 | IC50 |
18.46 μM
Compound: Tetrandrine
|
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 28109948] |
| SJRH30 | GI50 |
3 μM
Compound: 16
|
Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| U-937 | IC50 |
>50 μM
Compound: 16, NSC 77037
|
Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay
Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay
|
[PMID: 22766217] |
| Vero | CC50 |
14.92 μM
Compound: Tetrandrine
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
3 μM
Compound: Tetrandrine
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
| Vero C1008 | CC50 |
>33 μM
Compound: Tetrandrine (Fanchinine)
|
Toxicity CC50 against VERO-E6 cells determined at 48 hours by high content imaging (same conditions as 2_LEY without exposure to 0.01 MOI SARS CoV-2 virus)
Toxicity CC50 against VERO-E6 cells determined at 48 hours by high content imaging (same conditions as 2_LEY without exposure to 0.01 MOI SARS CoV-2 virus)
|
10.6019/CHEMBL4495565 |
| Vero C1008 | EC50 |
1.1 μM
Compound: Hanfangchin A
|
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
|
10.1101/2020.04.16.044016 |
| Vero C1008 | IC50 |
>5.01 × 105M
Compound: COVC-2820786116
|
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of VERO-E6 cells after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of VERO-E6 cells after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
10.6019/CHEMBL4651402 |
| Vero C1008 | IC50 |
11.66 μM
Compound: Tetrandrine (Fanchinine)
|
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of VERO-E6 cells after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of VERO-E6 cells after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
10.6019/CHEMBL4495565 |
| VSMC | IC50 |
1.48 μM
Compound: Tetrandrine
|
Antivegetative activity against rat VSMC
Antivegetative activity against rat VSMC
|
[PMID: 20708932] |
Chemical Information
-
CAS No. 23495-89-8
-
Masse moléculaire 622.75
-
Formule C38H42N2O6
-
SMILES
COC1=C2C3=C(C=C1OC)CCN(C)[C@@]3([H])CC4=CC=C(OC)C(OC5=CC=C(C[C@@]6([H])C7=CC(O2)=C(C=C7CCN6C)OC)C=C5)=C4
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Calcium Spark Assay
Calcium sparks are localized, transient increases in intracellular calcium concentration ([Ca2+]i) that occur in cardiac myocytes and represent elementary events underlying excitation-contraction coupling. These events are generated by the coordinated opening of clusters of ryanodine receptors (RyRs) on the sarcoplasmic reticulum membrane, leading to a brief release of Ca2+ into the cytosol. The detection and analysis of calcium sparks provide insights into the mechanisms of calcium handling and signaling in cardiac cells. Imaging techniques using fluorescent calcium indicators such as Fluo-3 are employed to visualize these subcellular calcium transients with high spatial and temporal resolution. The protocol is based on established methodologies described in primary literature for both experimental measurement and automated analysis of calcium sparks.
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)